How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses
Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.
How this was made
The 30-second read
Why it matters
Higher quarterly and YTD sales are presented alongside worsening net losses, increasing investor scrutiny on expense growth, reduced collaboration revenue, and the timing of plozasiran (REDEMPLO) commercial and regulatory milestones.
Market read
This is a company-specific earnings-results narrative emphasizing a profitability deterioration despite revenue growth, which can drive near-term valuation and risk-premium changes.
What to watch
The article does not provide cash balance, burn rate, or specific guidance; traders should verify liquidity runway and the magnitude/timing of collaboration revenue changes before extrapolating cash risk.
Background
Simply Wall St summarizes Arrowhead’s Q3 2026 results and discusses how the company’s RNAi platform and late-stage cardiometabolic programs are expected to offset current losses.
Ticker impact
Arrowhead reported Q3 2026 sales rising to $75.25M from $27.77M, while net loss widened to $194.28M and EPS loss increased.
Near-term downside bias or higher volatility as investors weigh revenue growth against expanding loss and cash runway risk.
The disclosed datapoints are directionally bearish on profitability (wider net loss, higher EPS loss) even as top-line growth is strong; the piece also emphasizes partner dependence and reduced collaboration revenue as ongoing risks.
Market effects
Reinforces biotech investor focus on RNAi platform execution and the ability to convert partner-driven revenue into sustainable profitability.
Limited, primarily impacts US biotech sentiment given Nasdaq-listed issuer focus.
Mentions European regulatory progress for plozasiran, which can influence international expectations for timelines and approvals.
Counterpoint
Investors may treat the revenue surge as an early inflection, arguing that losses are expected during scale-up and that upcoming late-stage data could re-rate the risk profile.
Key entities
- companyArrowhead Pharmaceuticals, Inc.
Nasdaq-listed biotech reporting Q3 2026 results with sharply higher sales but widening net loss and EPS loss.
- programplozasiran (REDEMPLO)
Arrowhead’s cardiometabolic late-stage program referenced as having positive European regulatory steps earlier in 2026.
